{
    "eid": "2-s2.0-85100350018",
    "title": "A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer",
    "cover-date": "2021-01-15",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Yen Shen Lu",
        "Keun Seok Lee",
        "Tsu Yi Chao",
        "Ling Ming Tseng",
        "Imjai Chitapanarux",
        "Shin Cheh Chen",
        "Chien Ting Liu",
        "Joohyuk Sohn",
        "Jee Hyun Kim",
        "Yuan Ching Chang",
        "Youngsen Yang",
        "Kanjana Shotelersuk",
        "Kyung Hae Jung",
        "Roberta Valenti",
        "Cassandra Slader",
        "Melissa Gao",
        "Yeon Hee Park"
    ],
    "citedby-count": 21,
    "ref-count": 43,
    "ref-list": [
        "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries",
        "Contrasting epidemiology and clinicopathology of female breast cancer in Asians versus the US population",
        "Incidence and mortality of female breast cancer in the Asia-Pacific region",
        "Insights into breast cancer in the east vs the west: a review",
        "Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies",
        "Ribociclib as first-line therapy for HR-positive, advanced breast cancer",
        "Palbociclib and letrozole in advanced breast cancer",
        "MONARCH 3: abemaciclib as initial therapy for advanced breast cancer",
        "4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)",
        "Overall survival with ribociclib plus endocrine therapy in breast cancer",
        "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial",
        "CDK4/6 inhibitors: game changers in the management of hormone receptor\u2013positive advanced breast cancer?",
        "Lilly aims to reshape Korea's breast cancer treatment market",
        "Novartis\u2019 breast cancer treatment wins regulator's nod",
        "Comprehensivemolecularportraitsofhumanbreast tumours",
        "Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial",
        "A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR\u00fe/HER2\u2013 metastatic breast cancer [abstract]",
        "Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant [abstract]",
        "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(\u00fe), HER2(-) advanced breast cancer: results from BOLERO-2",
        "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism",
        "TheimpactofPI3Kinhibitorson breast cancer cell and its tumor microenvironment",
        "Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer",
        "Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials",
        "Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial",
        "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)",
        "Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines",
        "Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials",
        "Phase I study of alpelisib (BYL719), an alpha-specific PI3K inhibitor, in Japanese patients with advanced solid tumors",
        "Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors",
        "Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management",
        "Clinical and histologic characterization of dermatologic adverse events from the pan-PI3K inhibitor buparlisib (BKM-120)",
        "Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions",
        "Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Taipei",
            "@id": "60031913",
            "affilname": "Chang Gung Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60020857",
            "affilname": "Samsung Medical Center, Sungkyunkwan university",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020857",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "New Taipei City",
            "@id": "60211913",
            "affilname": "Taipei Medical University Shuang-Ho Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60211913",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60115402",
            "affilname": "Yonsei Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60115402",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Seongnam",
            "@id": "60098516",
            "affilname": "Seoul National University Bundang Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60098516",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60069716",
            "affilname": "National Yang-Ming University Taiwan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069716",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60029238",
            "affilname": "Mackay Memorial Hospital Taiwan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029238",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60013314",
            "affilname": "Veterans General Hospital-Taipei",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013314",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60006240",
            "affilname": "University of Ulsan College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006240",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taichung",
            "@id": "60006121",
            "affilname": "Veterans General Hospital-Taichung Taiwan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006121",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Goyang",
            "@id": "124204628",
            "affilname": "National Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/124204628",
            "affiliation-country": "South Korea"
        }
    ],
    "funding": [
        "Novartis Pharmaceuticals",
        "Novartis Pharmaceuticals"
    ]
}